UNSPSC 51122603: Ezetimibe/simvastatin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV350. This VA Drug Class (CV350) classifies this compound as belonging to the group ANTILIPEMIC AGENTS.

UNSPSC 51122603 Ezetimibe/simvastatin, a Commodity-tier code, nominally covers a single statin-ezetimibe combination medication, but recent state and local procurement activity under this code reflects the broader emergency and chronic-care pharmaceutical procurement patterns that span across multiple drug classes and delivery contexts. State and local governments buying under this code range from city fire-rescue departments procuring acute-care medications through emergency medical services to state health authorities managing population-level pharmacy benefit programs and multistate cooperative purchasing consortia sourcing generic pharmaceuticals at scale. The City of Tampa's Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Department of Administration (administering the Minnesota Multistate Cooperative Purchasing Alliance) represent the issuing-body mix—municipal emergency services, state health authorities, and cooperative purchasing vehicles that serve multiple jurisdictions across regions.

Recent activity centers on three distinct procurement approaches. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications for Tampa Fire Rescue, soliciting four specific drug line items (Labetalol, Epinephrine, Adenosine, Diltiazem) with delivery within ten calendar days, a one-year contract term with renewal options, a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount, and an estimated contract value of $40,000.00. The Texas HHS Commission posted Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking direct-contracting strategies that bypass traditional pharmacy benefit managers and wholesalers. The Minnesota Department of Administration issued an RFP through MMCAP (Solicitation S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with pricing weighted at 75 percent, vendor insurance and cGMP certification required, and contract terms of two years with optional extensions. Geographic concentration appears strongest in the upper Midwest and Texas, with municipal-level activity in Florida; the recent opportunities span emergency medicine, state-level pharmacy benefit management, and multistate cooperative purchasing.